Monday 6-17-2014 Amgen Inc (AMGN) $AMGN opened at 116.75

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
Monday 6-17-2014 Amgen Inc (AMGN) $AMGN opened at 116.75 hitting the high price of 116.85 and a day low of 115.67 with a total volume of 2,219,026. AMGN had a previous close of 116.16 and has been seeing an average volume of 2,452,600.

Overall Average: 8% Buy

Recent stock forum discussions about AMGN http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!

Final Glance: Biotechnology companies
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)

Midday Glance: Biotechnology companies
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)

Early Glance: Biotechnology companies
AP - Tue Jun 17, 9:39AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)

3 Undervalued Amgen Growth Opportunities to Watch
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Jun 16, 4:30PM CDT
Amgen hasn't put as many eggs into the megablockbuster basket as Merck or Bristol-Myers Squibb , nor has it sought to utterly dominate a therapeutic area the way Biogen Idec may dominate MS. What Amgen does offer, though, is a deep pipeline... (full story)

Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
PR Newswire - Mon Jun 16, 3:03PM CDT
Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol. (full story)

Groundbreaking Collaborative Clinical Trial Launched
PR Newswire - Mon Jun 16, 8:00AM CDT
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca's global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial. (full story)

Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind  Bluebird's approach is so compelling that ... (full story)

The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
PR Newswire - Fri Jun 13, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (NYSE:CHL-Free Report), China Petroleum and Chemical Corp. (NYSE:SNP-Free Report), Trina Solar Limited (NYSE:TSL-Free Report), AstraZeneca (NYSE:AZN-Free Report) andAmgen (Nasdaq:AMGN-Free Report). (full story)

Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)

Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 4:10PM CDT
AstraZeneca (AZN) and partner Amgen (AMGN) announced that data from a phase II study evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine. (full story)

InterMune Up On Bullish View Of U.S. Esbriet Launch
at Investor's Business Daily - Thu Jun 12, 11:57AM CDT
Biotech InterMune (ITMN) hit a three-year high on the stock market today after UBS lifted its price target for the company on bullish expectations for a drug launch. UBS analyst Andrew Peters wrote that he expects Esbriet to become the standard of... (full story)

Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)

Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell (full story)

Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7t8xn/neuro_endocrine) has announced the addition of the "Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Ipsen S.A. - Novartis AG - Progenics Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Camurus AB - Vascular Biogenics Ltd. - Advanced Accelerator Applications - Foresee Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/j7..._endocrine (full story)

Amgen Inc. (AMGN) Stock Research Links

AMGN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 63

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 89

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 51

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 139

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 65

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 24

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
2027 Auto Brand Awards Put Long-Term Buyer Value First Again

Updated Category News Views 81

Car shoppers staring down high prices and financing costs do not need another shiny badge; they need some help separating durable value from showroom wallpaper. That is why the 2027 U.S. News vehicle brand awards, announced Nov. 19, 2026, are worth a look. They are not a sales forecast, not a profit forecast, and certainly not a reason to blindly crown a corporate winner....

Continue Reading
Trip.com Sets December 1 Date for Third-Quarter Results

Updated Category News Views 108

December’s first after-hours session will put Trip.com Group back under the market’s microscope, whether anybody is ready or not. The company says it will report results for the three months ended September 30, 2026 after the U.S. market closes on Tuesday, December 1. That is the whole hard-news payload for now: a reporting date, a call time, and no numbers to get...

Continue Reading

Top 5 Most Recently Viewed Articles

Greenwave Technology's Bold $4 Million Rare Earth Metals Strategy

Updated Category News Views 181

Greenwave Technology Solutions Takes Bold Steps Greenwave Technology Solutions, Inc. (NASDAQ: GWAV) recently announced a significant initiative to enhance its capabilities in rare earth metals recovery. This strategy entails raising $4 million through a securities purchase agreement with institutional and accredited investors. With a current market capitalization of...

Continue Reading
Exploring NewAmsterdam Pharma's Breakthrough Alzheimer’s Findings

Updated Category News Views 164

NewAmsterdam Pharma Unveils Exciting Alzheimer’s Data NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) has made strides in the study of Alzheimer’s disease. During a recent conference, the company presented compelling data from its BROADWAY trial, focusing on significant reductions in key Alzheimer’s biomarkers. This innovative research highlights obicetrapib's...

Continue Reading
Persistent Systems Reports Impressive Q3 Growth and Innovation

Updated Category News Views 202

Persistent Systems Achieves Strong Financial Performance Declares interim dividend of ?20 per share Persistent Systems (BSE: 533179) (NSE: PERSISTENT) has announced impressive financial results for the quarter ending December 31, showcasing a total revenue of $360.2 million. This success marks a 4.3% increase quarter-over-quarter and an outstanding 19.9% year-over-year...

Continue Reading
Nasdaq Announces Market Closure in Tribute to President Carter

Updated Category News Views 122

Nasdaq to Honor President Carter with Market Closure In a significant gesture of respect, Nasdaq (NASDAQ:NDAQ), a prominent market operator, will close all U.S. equities and options markets on January 9, 2025. This closure comes in memory of the former President Jimmy Carter, honoring his profound impact on American society. The announcement coincides with the nation’s...

Continue Reading
How a $100 Investment in Tenet Healthcare Could Grow Today

Updated Category News Views 187

The Remarkable Journey of Tenet Healthcare Tenet Healthcare (NYSE: THC) has shown impressive growth and resilience over the past 15 years. On average, the company has outstripped market returns by 5.36% annually, delivering an average annual return of 17.55%. With a current market capitalization of $17.35 billion, Tenet has proven to be a strong player in the healthcare...

Continue Reading